
Strand Eyes US, Southeast Asia Markets for Blood-Based Cancer Screening Test
What Happened?
Strand Life Sciences aims to expand its CancerSpot blood-based cancer screening test into international markets, targeting the US, Southeast Asia, and the Middle East. The company is pursuing FDA approval, expected to reach a key milestone by early next year.
Key points
- Strand Life Sciences is a subsidiary of Reliance Industries.
- CancerSpot uses genome sequencing and AI to identify cancer patterns in blood.
- The test can screen for 14 types of cancer.
- Strand aims to reduce the test price in India from ₹25,000 to under ₹10,000.
- A four-year study showed a 72% cancer detection rate with a 1.4% false-positive rate.
Key insights
- The FDA approval could open significant market opportunities in the US.
- Lowering the test price may increase accessibility for patients in India.
- The collaboration with hospitals could enhance the credibility of the test.
Why it matters
The expansion could improve cancer detection rates in regions with limited screening options.
Tags
Entities
Source
Business Standard


